Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Creative Medical Technology Holdings Successfully Completes Enrollment and ...

20 August 2026 · By · Wire by Fusion42

Published

20 August 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at biospace.com →

◆ Verified

Fusion42 · 20 August 2026 · Fusion42 review

Creative Medical Technology Holdings has completed enrollment and treatment across all cohorts in its FDA-cleared ADAPT trial for CELZ-201/Olastrocel, positioning the program for RMAT evaluation and Phase 3 planning with expected reduced trial costs and extended operating runway.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You can now focus on regulatory engagement with the FDA instead of recruitment challenges. Creative Medical’s shift to follow-up phase frees capital and opens a clearer path to late-stage approval discussions for non-opioid chronic pain therapy.

◆ Coverage

1 source · 20 Aug 2026

◆ Related on Wire

◆ Topics

Biotechclinical-trialregulatory-pathwaybiotechchronic-painregenerative-medicine